Ignite Creation Date:
2024-05-06 @ 7:59 PM
Last Modification Date:
2024-10-26 @ 3:17 PM
Study NCT ID:
NCT06201819
Status:
COMPLETED
Last Update Posted:
2024-01-18
First Post:
2023-12-14
Brief Title:
Liraglutide Effectiveness in Preoperative Weight-loss for Bariatric-metabolic Surgery
Sponsor:
Unidad de Cirugia Bariatrica Hospital Civil Dr Juan I Menchaca
Organization:
Unidad de Cirugia Bariatrica Hospital Civil Dr Juan I Menchaca
Study Overview
Official Title:
Liraglutide Effectiveness in Preoperative Weight-loss for Patients With Severe Obesity Undergoing Bariatric-metabolic Surgery
Status:
COMPLETED
Status Verified Date:
2024-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Severe obesity is associated with considerable reduction of wellbeing and life expectancy People living with severe obesity tend to die 8 to 10 years earlier Preoperative management of patients living with severe obesity can be challenging and proper weight-loss may help obtain better outcomes and less morbidity The effectiveness of GLP-1 analogue Liraglutide in preoperative weight-loss was evaluated in the study
Detailed Description:
Objective
Determine liraglutide effectiveness for preoperative weight-loss in patients with severe obesity undergoing bariatric-metabolic surgery
Methods
It is a single center quasi-experimental prospective before-and-after study All patients were assigned the same pharmacological treatment with liraglutide initiating dosing with 06 mg per day escalating 06 mg every week up to 30 mg The treatment dose was delivered once daily via subcutaneous injection for 3 months 12 weeks Weight-loss and percentage weight-loss was evaluated monthly using bioelectric impedance BIA final result at week 12
Determine liraglutide effectiveness for preoperative weight-loss in patients with severe obesity undergoing bariatric-metabolic surgery
Methods
It is a single center quasi-experimental prospective before-and-after study All patients were assigned the same pharmacological treatment with liraglutide initiating dosing with 06 mg per day escalating 06 mg every week up to 30 mg The treatment dose was delivered once daily via subcutaneous injection for 3 months 12 weeks Weight-loss and percentage weight-loss was evaluated monthly using bioelectric impedance BIA final result at week 12
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None